Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

Novo Nordisk (NVO) stock in focus as the company wins FDA accelerated nod for weight loss therapy Wegovy against the liver ...

Novo Nordisk A/S’s blockbuster weight-loss drug Wegovy received Food and Drug Administration approval to treat a serious form of liver disease, beating rival Eli Lilly & Co. to the US market for the ...

Eli Lilly & Co. raises Mounjaro prices in the United Kingdom to reduce costs in the U.S. Weight-loss drug prices increase by 170% in the U.K., but its National Health Service prices remained unchanged ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.

The NHS will prescribe the weight-loss jab Mounjaro to more people in response to a dramatic price increase for private ...

Chinese drugmaker Guangzhou Innogen Pharmaceutical had a strong debut in Hong Kong, cashing in on positive sentiment toward its flagship drug and Chinese biotech stocks in general.

Huge dividends from Denmark’s weight loss drug industry are result of high-tax and high-investment economy, says Nobel Prize winner Morten Meldal.

(Reuters) -Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...